GlassScriptPhysician profile
Joseph Tan
NPI 1396978144
$11,127.16
in general payments reported to CMS, 2019-2025
31 companies · $1,261 in 2025
The $1,261 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $2,357 · 2021: $848 · 2022: $2,961 · 2023: $988 · 2024: $1,480 · 2025: $1,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,721 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,721.04 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,175.84 | 2020-2022 | |
| Biotissue Holdings INC. | $1,708.64 | 2020-2024 | |
| Alcon Vision LLC | $1,383.83 | 2019-2025 | Rocklatan, Hydrus Microstent, Simbrinza |
| Abbvie INC. | $1,087.61 | 2022-2025 | Durysta, Ozurdex, Lumigan |
| Regeneron Healthcare Solutions, INC. | $950.57 | 2019-2025 | Eylea Hd, Eylea |
| Kala Pharmaceuticals, INC. | $450.24 | 2021-2022 | |
| New World Medical,INC. | $433.52 | 2022-2023 | |
| Amgen INC. | $402.50 | 2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $351.83 | 2019-2025 | Cequa |
| Glaukos Corporation | $295.78 | 2020-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Oyster Point Pharma, INC. | $272.96 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $236.79 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $236.73 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $187.50 | 2024-2025 | Xdemvy |
| Ivantis, INC | $150.38 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $139.15 | 2022-2024 | Omni Surgical System |
| Carl Zeiss Meditec, INC. | $100.82 | 2019-2024 | |
| Aerie Pharmaceuticals, INC. | $96.95 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $85.28 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $73.39 | 2023-2024 | Syfovre |
| Bausch & Lomb Americas INC. | $63.79 | 2023-2025 | Miebo, Xiidra |
| Astellas Pharma US INC | $58.96 | 2024-2025 | Izervay |
| Dompe US, INC. | $39.10 | 2021-2024 | Oxervate |
| Eyevance Pharmaceuticals LLC | $28.68 | 2022-2023 | Flarex |
| Shire North American Group INC | $19.75 | 2019 | |
| Celularity INC. | $19.67 | 2021 | |
| Ferring Pharmaceuticals INC. | $18.15 | 2023 | Rebyota |
| Omeros Corporation | $18.03 | 2019 | |
| Genentech USA, INC. | $16.70 | 2022 | |
| Ocular Therapeutix, INC. | $14.53 | 2023 | Dextenza |
| Avedro INC. | $9.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.